Topline data from Phase 2b/3 trial of izokibep as a treatment for non-infectious non-anterior uveitis expected in December 2024 Positive lonigutamab EOP2 FDA interaction completed and initiation of ...
PONGOLA 40MW SITE Phase 1BESS installations are strategically located in ... Each potential site was evaluated against ...
REGENXBIO Inc. (Nasdaq: RGNX) today reported financial results and recent operational highlights for the third quarter ended September 30, 2024.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback